UTHR Reddit Mentions

At $556.82, United Therapeutics is trading meaningfully above its 200‑day moving average of $481.36, indicating a longer‑term uptrend despite a 4.2% pullback over the last month. The current valuation and price level suggest the stock has already enjoyed a strong run, and the recent decline looks more like consolidation than a clear reversal.

• Price is roughly 16% above the 200‑day moving average ($556.82 vs. $481.36), a classically bullish long‑term technical signal that reflects sustained positive momentum.
• The 4.2% decline over the last month points to near‑term weakness or profit‑taking, but not yet enough to break the broader uptrend implied by the 200‑day moving average.
• With a PE of 20.58 and strong EPS, the stock does not appear excessively stretched on earnings alone, but trading well above the 200‑day average suggests some risk of further short‑term volatility if sentiment cools or results disappoint.

United Therapeutics shows fundamentally strong profitability and a solid long‑term uptrend, but near‑term technical softness and weak alternative data momentum temper the outlook. Overall, the setup appears balanced: earnings quality supports the stock, while hiring cuts and modest engagement data argue for measured expectations rather than aggressive optimism.

• Bullish fundamentals (high EPS, reasonable PE, and price above the 200‑day moving average) support a constructive long‑term view on the company’s earnings power.
• Soft alternative data—especially the sharp decline in job postings and limited digital/social traction—combined with a recent 4.2% price pullback, suggest a more cautious, neutral stance on near‑term stock performance.